Prostate cancer is one of the most common types of cancer that affects patients. In the United States, lifetime risk of prostate cancer is approximately 11%, and the lifetime risk of dying of prostate cancer is 2.5%. Many patients will die with prostate cancer but not necessarily of prostate cancer. In autopsy studies, 20% of patients aged 50 to 59 years old and more than 33% of patients aged 70 to 79 years old were found to have prostate cancer. The overall median age of death from prostate cancer is 80, with more than two-thirds of all patients who die of prostate cancer being older than 75 years old. Measuring the amount of prostate specific antigen (PSA) can be a helpful tool in diagnosing prostate cancer. While population-wide screening is not currently recommended, there is a role for shared decision making for certain groups.
Goal of Prostate Cancer Screening
Benefits of Early Detection and Treatment
Harms Associated with Screening
Individuals Aged 55 Through 69
For Individuals Aged 70 and Older
High Risk Populations
AUA: Early detection of prostate cancer
USPSTF: Screening for Prostate Cancer – US Preventive Services Task Force Recommendation Statement
ACS: Prostate Cancer Screening
Are you an
ObG Insider?
Get specially curated clinical summaries delivered to your inbox every week for free
Please log in to ObGFirst to access this page
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan
You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site